ByteDance Finalizes Majority U.S.-Owned TikTok Joint Venture to Avert American Ban 
Nintendo Stock Jumps as Switch 2 Becomes Best-Selling Console in the U.S. in 2025 
Court Allows Expert Testimony Linking Johnson & Johnson Talc Products to Ovarian Cancer 
Morgan Stanley Flags High Volatility Ahead for Tesla Stock on Robotaxi and AI Updates 
Valero Makes First Venezuelan Crude Purchase Under New U.S.-Caracas Deal 
Apple China Holiday Sale Offers Discounts Up to 1,000 Yuan on Popular Devices 
Global DRAM Chip Shortage Puts Automakers Under New Cost and Supply Pressure 
Lynas Rare Earths Shares Surge as Quarterly Revenue Jumps on Strong Prices 
Elon Musk Says Tesla Cybercab and Optimus Production Will Start Slowly Before Rapid Growth 
United Airlines Posts Record Q4 Revenue as Premium Demand Lifts Earnings 
FSU Criticizes ANZ Over Suncorp Bank Job Cuts Amid Post-Acquisition Commitments 
Netflix Stock Slips After Earnings as Soft 2026 Guidance Overshadows Subscriber Milestone 
Walmart to Cut PhonePe Stake in IPO as Tiger Global and Microsoft Exit 
Rio Tinto Posts Strong Q4 Iron Ore and Copper Output on Operational Recovery 
FAA Says It Is Not Blocking Boeing 737 MAX 7 and MAX 10 Certification 
Trump Signs Executive Order to Limit Wall Street Investment in Single-Family Homes 
EXTON, Pa., May 03, 2017 -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, will report financial results for the first quarter ended March 31, 2017 and recent operational highlights on Wednesday, May 10, 2017, before the open of the U.S. financial markets. Fibrocell will also host a conference call and webcast at 8:30 a.m. EDT on the same day to discuss its financial results and operational highlights. A question-and-answer session will follow Fibrocell’s remarks.
To participate on the live call, please dial 888-539-3613 (domestic) or +1-719-457-2552 (international), and provide the conference code 9682774 five to ten minutes before the start of the call. The conference call will also be webcast live under the investor relations section of Fibrocell's website at www.fibrocell.com/investors/events and will be archived there for 30 days following the call. Please visit Fibrocell's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.
About Fibrocell
Fibrocell is an autologous cell and gene therapy company translating personalized biologics into medical breakthroughs for diseases affecting the skin and connective tissue. Fibrocell’s most advanced product candidate, FCX-007, has begun a Phase 1/2 trial for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). Fibrocell is in pre-clinical development of FCX-013, its product candidate for the treatment of linear scleroderma. In addition, Fibrocell has a third program in the research phase for the treatment of arthritis and related conditions. Fibrocell’s gene therapy portfolio is being developed in collaboration with Intrexon Corporation (NYSE:XON), a leader in synthetic biology. For more information, visit http://www.fibrocell.com or follow us on Twitter at @Fibrocell, and LinkedIn.
Investor & Media Relations Contact: Karen Casey 484-713-6133 [email protected]
